ZA201401333B - Protein-based therapy and diagnosing of tau-mediated pathology in alzheimer's disease - Google Patents

Protein-based therapy and diagnosing of tau-mediated pathology in alzheimer's disease

Info

Publication number
ZA201401333B
ZA201401333B ZA2014/01333A ZA201401333A ZA201401333B ZA 201401333 B ZA201401333 B ZA 201401333B ZA 2014/01333 A ZA2014/01333 A ZA 2014/01333A ZA 201401333 A ZA201401333 A ZA 201401333A ZA 201401333 B ZA201401333 B ZA 201401333B
Authority
ZA
South Africa
Prior art keywords
tau
alzheimer
diagnosing
protein
disease
Prior art date
Application number
ZA2014/01333A
Other languages
English (en)
Inventor
Norbert Zilka
Branislav Kovacech
Eva Kontsekova
Michal Novak
Original Assignee
Axon Neuroscience Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47216372&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201401333(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Axon Neuroscience Se filed Critical Axon Neuroscience Se
Publication of ZA201401333B publication Critical patent/ZA201401333B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
ZA2014/01333A 2011-09-19 2014-02-21 Protein-based therapy and diagnosing of tau-mediated pathology in alzheimer's disease ZA201401333B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161536339P 2011-09-19 2011-09-19
US201261653115P 2012-05-30 2012-05-30
PCT/IB2012/002246 WO2013041962A1 (en) 2011-09-19 2012-09-14 Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease

Publications (1)

Publication Number Publication Date
ZA201401333B true ZA201401333B (en) 2015-09-30

Family

ID=47216372

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2014/01333A ZA201401333B (en) 2011-09-19 2014-02-21 Protein-based therapy and diagnosing of tau-mediated pathology in alzheimer's disease

Country Status (30)

Country Link
US (5) US9518101B2 (enExample)
EP (2) EP2758433B1 (enExample)
JP (7) JP6253583B2 (enExample)
KR (3) KR20210099167A (enExample)
CN (3) CN104185640B (enExample)
AU (3) AU2012311234B2 (enExample)
BR (1) BR112014006376B1 (enExample)
CA (1) CA2848346A1 (enExample)
CL (3) CL2014000679A1 (enExample)
CY (1) CY1119792T1 (enExample)
DK (1) DK2758433T3 (enExample)
ES (1) ES2656442T3 (enExample)
HR (1) HRP20180083T8 (enExample)
HU (1) HUE036177T2 (enExample)
IL (4) IL231201B (enExample)
LT (1) LT2758433T (enExample)
ME (1) ME03008B (enExample)
MX (2) MX347505B (enExample)
MY (1) MY183989A (enExample)
PL (1) PL2758433T3 (enExample)
PT (1) PT2758433T (enExample)
RS (1) RS56852B1 (enExample)
RU (2) RU2018102103A (enExample)
SG (4) SG10201703771WA (enExample)
SI (1) SI2758433T1 (enExample)
SM (1) SMT201800109T1 (enExample)
TR (1) TR201800669T4 (enExample)
UA (2) UA123390C2 (enExample)
WO (1) WO2013041962A1 (enExample)
ZA (1) ZA201401333B (enExample)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012106363A2 (en) * 2011-01-31 2012-08-09 Intellect Neurosciences Inc. Treatment of tauopathies
SMT201800109T1 (it) * 2011-09-19 2018-05-02 Axon Neuroscience Se Terapia a base di proteine e diagnosi di una patologia mediata da tau nella malattia di alzheimer
WO2014008404A1 (en) 2012-07-03 2014-01-09 Washington University Antibodies to tau
JP6290212B2 (ja) 2012-08-16 2018-03-07 アイピエリアン，インコーポレイティド タウオパチーの処置方法
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
JP6674888B2 (ja) 2013-03-13 2020-04-01 プロセナ バイオサイエンシーズ リミテッド タウ免疫療法
JP6629201B2 (ja) * 2013-11-27 2020-01-15 アイピエリアン，インコーポレイティド タウオパチーの処置方法
WO2015098963A1 (ja) * 2013-12-26 2015-07-02 東亞合成株式会社 カルレティキュリンの発現促進方法および該方法に用いられる合成ペプチド
NZ630610A (en) 2014-02-14 2019-05-31 Ipierian Inc Tau peptides, anti-tau antibodies, and methods of use thereof
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
CA2952745A1 (en) * 2014-06-26 2015-12-30 Janssen Vaccines & Prevention B.V. Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
TW202136296A (zh) 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
BR112017006419A2 (pt) 2014-09-30 2017-12-19 Univ Washington medições cinéticas de tau
KR102584655B1 (ko) 2014-11-14 2023-10-06 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
PT3221349T (pt) 2014-11-19 2021-01-21 Axon Neuroscience Se Anticorpos tau humanizados na doença de alzheimer
TWI669314B (zh) 2015-02-26 2019-08-21 美國禮來大藥廠 針對ｔａｕ之抗體及其用途
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP3303386B1 (en) 2015-06-05 2024-08-28 Genentech, Inc. Anti-tau antibodies and methods of use
CN107849105B (zh) 2015-07-06 2021-09-17 Ucb生物制药有限责任公司 Tau结合抗体
CA2991451A1 (en) 2015-07-06 2017-01-12 Ucb Biopharma Sprl Tau-binding antibodies
JO3711B1 (ar) * 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
GB201518675D0 (en) * 2015-10-21 2015-12-02 Cellcap Technologies Ltd Detection of structural forms of proteins
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3452509A1 (en) 2016-05-02 2019-03-13 Prothena Biosciences Limited Antibodies recognizing tau
CN109219615B (zh) * 2016-05-02 2022-12-09 普罗塞纳生物科学有限公司 识别tau的抗体
PL3452507T3 (pl) 2016-05-02 2023-01-09 Prothena Biosciences Limited Immunoterapia tau
RU2758488C2 (ru) 2016-05-18 2021-10-28 Вояджер Терапьютикс, Инк. Модулирующие полинуклеотиды
KR101997319B1 (ko) * 2016-06-21 2019-07-08 전남대학교산학협력단 이형태체 항원인식 항체 생산을 유도하는 플라젤린 백신보조제 기반의 백신의 제조 및 그 응용
US10988529B2 (en) 2016-08-09 2021-04-27 Eli Lilly And Company Combination therapy
FR3058143B1 (fr) * 2016-10-27 2021-03-12 Univ Grenoble Alpes Nanocorps anti-tau
AU2017373889B2 (en) 2016-12-07 2025-01-02 Ac Immune Sa Anti-Tau antibodies and methods of use
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
CN110248959B (zh) 2016-12-07 2023-06-30 基因泰克公司 抗tau抗体和使用方法
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11001615B2 (en) 2016-12-21 2021-05-11 Adel Inc. Mutated tau protein fragment and use thereof
KR20190134997A (ko) 2017-02-17 2019-12-05 데날리 테라퓨틱스 인크. 항-tau 항체 및 이의 사용 방법
CN110418804A (zh) * 2017-03-28 2019-11-05 扬森疫苗与预防公司 与tau特异性地结合的结合分子
US20210147481A1 (en) * 2017-04-21 2021-05-20 Ohio University Peptide-based inhibitors of mark family proteins
CN110881274B (zh) * 2017-05-02 2024-11-15 普罗塞纳生物科学有限公司 识别tau的抗体
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
JP7029718B2 (ja) * 2017-07-31 2022-03-04 国立研究開発法人量子科学技術研究開発機構 リン酸化タウタンパク質の測定方法
JP7160929B2 (ja) 2017-10-02 2022-10-25 ブラックソーン セラピューティクス インコーポレイテッド 神経画像処理及び遺伝子発現マッピングデータのコンピュータ生成型予測応用のための方法及びシステム
TWI750419B (zh) * 2017-10-16 2021-12-21 日商衛材R&D企管股份有限公司 抗tau抗體及其用途
KR102710762B1 (ko) 2017-10-25 2024-09-25 얀센 파마슈티칼즈, 인코포레이티드 인산화 타우 펩티드의 조성물 및 이의 용도
EP3700558A4 (en) * 2017-10-27 2022-03-09 United Neuroscience TAU PEPTIDE IMMUNOGENIC CONSTRUCTIONS
WO2019120527A1 (en) * 2017-12-20 2019-06-27 Michael Heneka Novel means and methods for treating neurodegenerative diseases
WO2019175735A1 (en) 2018-03-11 2019-09-19 Koorosh Shahpasand Conformation-independent antibodies against neurotoxic tau proteins
MX2020009991A (es) * 2018-03-28 2020-10-14 Axon Neuroscience Se Metodos basados en anticuerpos para detectar y tratar la enfermedad de alzheimer.
RU2679080C1 (ru) * 2018-04-17 2019-02-05 Александр Олегович Морозов Пептид и способ лечения болезни альцгеймера
RU2679059C1 (ru) * 2018-04-17 2019-02-05 Александр Олегович Морозов Пептид и способ лечения болезни альцгеймера
AU2019262220B2 (en) * 2018-05-03 2025-10-16 Washington University Methods of diagnosing and treating based on site-specific tau phosphorylation
US11085935B2 (en) 2018-05-03 2021-08-10 Washington University Methods of treating based on site-specific tau phosphorylation
MY206038A (en) * 2018-07-03 2024-11-26 Hoffmann La Roche Oligonucleotides for modulating tau expression
CA3107788A1 (en) 2018-07-31 2020-02-06 Eli Lilly And Company Combination of anti-tau antibody and oga inhibitor for treatment of diseases characterized by aberrant tau aggregation
WO2020097561A1 (en) * 2018-11-08 2020-05-14 Prothena Biosciences Limited Antibodies recognizing tau
WO2020106598A1 (en) * 2018-11-19 2020-05-28 The Board Of Regents Of The University Of Texas System Tau peptide antigens and antibodies binding thereto for the treatment of tauopathies
WO2020120644A1 (en) * 2018-12-13 2020-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) New anti tau svqivykpv epitope single domain antibody
KR20210125048A (ko) 2019-02-08 2021-10-15 에이씨 이뮨 에스.에이. 인산화 타우 펩티드 백신의 안전한 투여 방법
JP7681316B2 (ja) * 2019-02-08 2025-05-22 プロセナ バイオサイエンシーズ リミテッド タウを認識する抗体
AU2020231366A1 (en) 2019-03-03 2021-08-12 Prothena Biosciences Limited Antibodies recognizing tau
EP3947446A1 (en) * 2019-03-25 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Treatment of taupathy disorders by targeting new tau species
CN114173812A (zh) * 2019-04-24 2022-03-11 杨森制药公司 Tau疫苗的异源给予
EA202192888A1 (ru) * 2019-05-31 2022-03-23 Эли Лилли Энд Компани Соединения и способы нацеливания на тау человека
GB201909393D0 (en) 2019-06-28 2019-08-14 Gen2 Neuroscience Ltd Tau epitope and binding molecules
KR102509648B1 (ko) * 2019-08-06 2023-03-15 아프리노이아 테라퓨틱스 리미티드 병리학적 타우 종에 결합하는 항체 및 이의 용도
WO2021030615A1 (en) * 2019-08-13 2021-02-18 Washington University Methods to detect mtbr tau isoforms and use thereof
US20220275038A1 (en) * 2019-08-15 2022-09-01 Tokyo Medical University Clsp derivative incapable of being affected by clsp inhibiting substance, and clsp activity enhancing/protecting agent
US20220402979A1 (en) * 2019-09-09 2022-12-22 Axon Neuroscience Se Biomarkers and treatments of alzheimer's disease and mild cognitive impairment
US12493043B2 (en) 2019-09-10 2025-12-09 Washington University Blood-based assay for diagnosing and treating based on site-specific tau phosphorylation
JP2022553329A (ja) * 2019-10-22 2022-12-22 バイオジェン・エムエイ・インコーポレイテッド アルツハイマー病を治療するための抗ベータ－アミロイド抗体
IL270800A (en) * 2019-11-20 2021-05-31 Yeda Res & Dev A method for treating Alzheimer's disease
CN110841059A (zh) * 2019-12-03 2020-02-28 南通大学 老年性痴呆小鼠模型的制备方法
TWI853145B (zh) * 2020-02-05 2024-08-21 日商住友製藥股份有限公司 Tau蛋白病變及失智症相關疾病之判定藥及判定方法
BR112022023366A2 (pt) * 2020-05-19 2023-05-02 Othair Prothena Ltd Vacina com múltiplos epítopos para o tratamento de mal de alzheimer
US12281166B2 (en) 2020-05-26 2025-04-22 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3
AR122129A1 (es) * 2020-08-07 2022-08-17 Prothena Biosciences Ltd Vacuna de tau para el tratamiento de la enfermedad de alzheimer
KR20230080397A (ko) * 2020-08-07 2023-06-07 오타이르 프로테나 리미티드 알츠하이머 질환을 치료하기 위한 멀티에피토프 백신
US20240003918A1 (en) 2020-11-30 2024-01-04 Enigma Biointelligence, Inc. Non-invasive assessment of alzheimer's disease
EP4262754A1 (en) * 2020-12-18 2023-10-25 Sangamo Therapeutics, Inc. Improved pharmaceutical compositions containing adeno-associated viral vector
TW202246320A (zh) * 2021-02-14 2022-12-01 愛爾蘭商普羅帝納生物科學公司 使用識別ｔａｕ之抗體之方法
BR112023014151A2 (pt) * 2021-02-19 2023-10-10 Eisai R&D Man Co Ltd Anticorpo tau anti-pt217
US12144815B2 (en) 2021-02-23 2024-11-19 Hoth Therapeutics, Inc. Use of aprepitant for treating Alzheimer's disease
CL2021001380A1 (es) 2021-05-26 2022-01-14 Corporacion Centro Int De Biomedicina Icc Generación de un nuevo anticuerpo monoclonal sitio específico para la proteína tau y su uso como herramienta en biomarcadores específicos para la detección temprana de enfermedades neurodegenerativas y patologías involucradas con la proteína tau como alzheimer y otras demencias.
CN113430230A (zh) * 2021-06-24 2021-09-24 南通大学 tau截断体蛋白在诱导tau病理聚集中的应用
EP4413366A4 (en) * 2021-10-08 2025-09-10 Tiberias Tech Hk Limited TIBTECH METHODS AND COMPOSITIONS FOR THE DETECTION OF CDH17
CN113861441A (zh) * 2021-10-28 2021-12-31 南开大学 一种tau蛋白特异的纳米分子伴侣的制备方法及其在抑制tau聚集中的应用
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
CN116554342A (zh) * 2022-01-29 2023-08-08 元本(珠海横琴)生物科技有限公司 一种融合表达Tau-4R蛋白的大肠杆菌工程菌株
EP4486387A1 (en) 2022-02-28 2025-01-08 Tridem Bioscience GmbH & Co KG A conjugate consisting of or comprising at least a ss-glucan or a mannan
KR20250069606A (ko) 2022-09-15 2025-05-19 보이저 테라퓨틱스, 인크. 타우 결합 화합물
WO2025019332A1 (en) * 2023-07-14 2025-01-23 Alzpath, Inc. Methods for remote blood collection, extraction and analysis of neuro biomarkers
WO2025109524A1 (en) 2023-11-22 2025-05-30 Ac Immune Sa Assays and methods for assessing vaccine preparations
CN117624354B (zh) * 2023-11-30 2024-07-12 无锡傲锐东源生物科技有限公司 一种抗人乙酰化tau281兔单克隆抗体及其应用
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4360019A (en) 1979-02-28 1982-11-23 Andros Incorporated Implantable infusion device
US4424200A (en) 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4692147A (en) 1980-04-02 1987-09-08 Medtronic, Inc. Drug administration device
US4479930A (en) 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4725852A (en) 1985-05-09 1988-02-16 Burlington Industries, Inc. Random artificially perturbed liquid apparatus and method
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5811310A (en) * 1986-09-30 1998-09-22 Albert Einstein College Of Medicine Of Yeshiva Univ. The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
DE3853515T3 (de) 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
EP0362371A4 (en) 1988-04-15 1990-10-24 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
CA2067194C (en) 1989-10-05 2003-03-18 Glenn Kawasaki Cell-free synthesis and isolation of novel genes and polypeptides
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
GB9020282D0 (en) 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
WO1993011231A1 (en) * 1991-12-06 1993-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Tools for the diagnosis and treatment of alzheimer's disease
WO1994012629A1 (en) 1992-12-02 1994-06-09 Baylor College Of Medicine Episomal vectors for gene therapy
JPH09501936A (ja) 1993-08-26 1997-02-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 生物活性ペプチドをコードする裸のポリヌクレオチドを投与するための方法、組成物および装置
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
KR100275591B1 (ko) * 1994-10-28 2001-02-01 크리스타 헤르 조크 단백질 키나아제 npk-110
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
US5643207A (en) 1995-04-28 1997-07-01 Medtronic, Inc. Implantable techniques for infusing a therapeutic agent with endogenous bodily fluid
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
EP1281718A3 (en) 1995-11-10 2005-01-19 ELAN CORPORATION, Plc Peptides which enhance transport across tissues
US5820589A (en) 1996-04-30 1998-10-13 Medtronic, Inc. Implantable non-invasive rate-adjustable pump
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
WO2000030680A1 (en) 1998-11-23 2000-06-02 Idec Pharmaceuticals Corporation Tumor antigen-specific antibody-gp39 chimeric protein constructs
US6198966B1 (en) 1999-02-26 2001-03-06 Medtronic, Inc. Recirculating implantable drug delivery system
JP3383618B2 (ja) 1999-08-18 2003-03-04 松下電器産業株式会社 移動体通信端末装置及び受信強度検出方法
ATE326700T1 (de) 1999-09-09 2006-06-15 Max Planck Gesellschaft SCREENING NACH INHIBITOREN VON ßGEPAARTEN HELIKALEN FILAMENTENß
CA2384146A1 (en) * 1999-09-09 2001-03-15 Guy Rouleau Diagnosis, prognosis and treatment of trinucleotide repeat-associated diseases and intranuclear inclusions-associated diseases
US6589746B1 (en) 1999-10-21 2003-07-08 University Of Cincinnati Method of detecting axonally-derived protein tau in patients with traumatic CNS injury
AT500379B8 (de) 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
DE50111493D1 (de) 2001-09-03 2007-01-04 Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh Antigen-Mimotope und Vakzine gegen Krebserkrankungen
TWI226905B (en) 2001-10-19 2005-01-21 Bioware Technology Co Ltd Low pressure-accelerated particle gene gun
JP4414332B2 (ja) * 2002-07-12 2010-02-10 アクソン・ニューロサイエンス・フォルシュングス−ウント・エントヴィックルングス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング アルツハイマーｔａｕタンパク質を発現するトランスジェニック動物
CA2487528A1 (en) * 2002-07-24 2004-02-12 Innogenetics N.V. Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation
US7521230B2 (en) * 2002-10-16 2009-04-21 Board Of Regents Of The University Of Nebraska Nucleic acid encoding a Brain Derived Tau Kinase polypeptide and methods of use thereof
EP1516930A1 (en) 2003-09-16 2005-03-23 Georg-August Universität Göttingen Cellular model of tauopathies for lead identification and drug discovery
MXPA06003886A (es) 2003-10-08 2006-08-11 Ebioscience Reactivos de enlace de inmunoglobulina naturales y metodos de fabricacion y uso de los mismos.
CN1721437A (zh) * 2004-07-13 2006-01-18 中南大学 一种与Tau蛋白相关的多肽抗原及抗体
US8012936B2 (en) * 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US20070280935A1 (en) * 2006-04-07 2007-12-06 Bernd Bohrmann Antibody that recognizes phosphorylated peptides
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
ATE524487T1 (de) * 2007-01-11 2011-09-15 Univ Ramot Tau peptidmimetikum zur behandlung von neurodegenerativen erkrankungen
TR201802286T4 (tr) * 2007-04-20 2018-03-21 The Chemo Sero Therapeutic Res Institute Peptidle bağışıklık yanıtının arttırılması için yöntem.
WO2009000520A1 (en) * 2007-06-25 2008-12-31 Universität Duisburg-Essen Screening-method for polymorphic markers in htra1 gene in neurodegenerative disorders
UA107571C2 (xx) * 2009-04-03 2015-01-26 Фармацевтична композиція
EP4218794A3 (en) 2009-06-10 2023-09-13 New York University Immunological targeting of pathological tau proteins
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
WO2011026031A1 (en) * 2009-08-28 2011-03-03 The Board Of Regents Of The University Of Texas System Antibodies that bind tau oligomers
WO2011053565A2 (en) 2009-10-29 2011-05-05 Biomedical Sciences Research Centre "Alexander Fleming" Compositions and methods for detecting a tauopathy
DK2496594T3 (en) 2009-11-06 2018-03-05 The J David Gladstone Inst METHODS AND COMPOSITIONS FOR MODULATING TAU LEVELS
DK2501716T3 (en) * 2009-11-19 2015-04-07 Solis Biodyne Oü Formations to increase polypeptidstabilitet and activity and related practices
CL2010000019A1 (es) 2010-01-11 2010-06-11 Univ Chile Anticuerpo monoclonal contra el tnf humano y sus fragmentos, secuencias nucleotidicas que lo codifican, vector de expresion y celulas que las contienen, composiciones y kit que comprenden el anticuerpo, uso de los mismos y metodo para su obtencion.
SMT201800109T1 (it) * 2011-09-19 2018-05-02 Axon Neuroscience Se Terapia a base di proteine e diagnosi di una patologia mediata da tau nella malattia di alzheimer
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
BR112014006376A2 (pt) 2017-06-13
US9845352B2 (en) 2017-12-19
BR112014006376B1 (pt) 2021-07-27
ES2656442T3 (es) 2018-02-27
CY1119792T1 (el) 2018-06-27
WO2013041962A1 (en) 2013-03-28
LT2758433T (lt) 2018-02-12
DK2758433T3 (en) 2018-01-15
IL274440B (en) 2021-12-01
HUE036177T2 (hu) 2018-06-28
HRP20180083T8 (hr) 2018-07-27
AU2020200624A1 (en) 2020-02-20
AU2012311234B2 (en) 2017-09-28
CA2848346A1 (en) 2013-03-28
KR20200084362A (ko) 2020-07-10
IL287794A (en) 2022-01-01
SG11201400125RA (en) 2014-03-28
HRP20180083T1 (hr) 2018-02-23
KR20140063853A (ko) 2014-05-27
RU2014115481A (ru) 2015-10-27
US9828421B2 (en) 2017-11-28
JP2018117631A (ja) 2018-08-02
MX391157B (es) 2025-03-21
CL2015001314A1 (es) 2015-09-21
MY183989A (en) 2021-03-17
KR20210099167A (ko) 2021-08-11
IL259775B (en) 2020-05-31
US20170145082A1 (en) 2017-05-25
CN109265543B (zh) 2022-04-26
AU2017272259B2 (en) 2019-11-14
MX2014003357A (es) 2015-03-20
EP3275461A1 (en) 2018-01-31
RU2018102103A (ru) 2019-02-21
SG10201703771WA (en) 2017-06-29
EP2758433A1 (en) 2014-07-30
JP2017042172A (ja) 2017-03-02
US12404322B2 (en) 2025-09-02
US9518101B2 (en) 2016-12-13
CN115417916A (zh) 2022-12-02
JP6637124B2 (ja) 2020-01-29
CL2016000215A1 (es) 2017-08-18
TR201800669T4 (tr) 2018-03-21
US20220010004A1 (en) 2022-01-13
US20180282401A1 (en) 2018-10-04
AU2017272259A1 (en) 2018-01-04
SMT201800109T1 (it) 2018-05-02
JP2014530597A (ja) 2014-11-20
AU2020200624B2 (en) 2021-12-23
JP7182316B2 (ja) 2022-12-02
PT2758433T (pt) 2018-01-19
AU2020200624A9 (en) 2021-12-23
JP2018183160A (ja) 2018-11-22
JP6360869B2 (ja) 2018-07-18
PL2758433T3 (pl) 2018-06-29
CN104185640A (zh) 2014-12-03
RU2018102103A3 (enExample) 2021-05-31
CN104185640B (zh) 2018-07-20
SG10201912964PA (en) 2020-02-27
MX347505B (es) 2017-04-28
UA123390C2 (uk) 2021-03-31
UA115657C2 (uk) 2017-12-11
JP6286590B2 (ja) 2018-02-28
IL231201A0 (en) 2014-04-30
IL259775A (en) 2018-07-31
RU2645259C2 (ru) 2018-02-19
RS56852B1 (sr) 2018-04-30
US20170260263A1 (en) 2017-09-14
CN109265543A (zh) 2019-01-25
KR102130439B1 (ko) 2020-07-07
HK1199459A1 (en) 2015-07-03
EP2758433B1 (en) 2017-10-18
KR102285743B1 (ko) 2021-08-06
US20150050215A1 (en) 2015-02-19
CL2014000679A1 (es) 2014-11-21
AU2012311234A1 (en) 2014-05-01
US11098106B2 (en) 2021-08-24
SI2758433T1 (en) 2018-02-28
JP2017093470A (ja) 2017-06-01
JP6253583B2 (ja) 2017-12-27
JP6499345B2 (ja) 2019-04-10
SG10201912955PA (en) 2020-02-27
IL274440A (en) 2020-06-30
ME03008B (me) 2018-10-20
JP6950981B2 (ja) 2021-10-20
JP2022031631A (ja) 2022-02-22
JP2020072675A (ja) 2020-05-14
IL231201B (en) 2018-06-28

Similar Documents

Publication Publication Date Title
IL287794A (en) Protein-based therapy and diagnosis of tau-mediated pathology in Alzheimer's disease
AP2014007601A0 (en) Novel purine derivatives and their use in the treatment of disease
IL237369A0 (en) Methods for treating Alzheimer's disease and pharmaceutical compositions thereof
GB201105137D0 (en) Therapeutic molecules for use in the suppression of Parkinson's disease
IL230957B (en) Pharmacy methods and preparations for the treatment of an eye disease in a patient
IL230441A0 (en) Diagnosis of Alzheimer's disease
IL234779A (en) Intracellular markers for Alzheimer's detection and monitoring of disease progression
EP2568811A4 (en) TREATMENT OF EASY COGNITIVE IMMUNITY AND MORBUS ALZHEIMER
PT2603238E (pt) Métodos e composições farmacêuticas para o tratamento de uma doença ocular num indíviduo
IL237730B (en) Treatment of mild and moderate Alzheimer's disease
SG10201801200PA (en) An h3 receptor antagonist for use in the treatment of alzheimer's disease
PL2565184T3 (pl) Środek terapeutyczny i środek zapobiegawczy przeciwko chorobie alzheimera
ZA201402477B (en) Compounds for use in the treatment of alzheimer's disease
IL239078A0 (en) Protein for use in the treatment of eye diseases
IL231115A0 (en) Peptides for use in the treatment of diseases and disorders related to - 1 - il
PL2593129T3 (pl) Nonapeptyd pat do stosowania w leczeniu choroby alzheimera
GB201104720D0 (en) Carncin - The use of L-carnosine and cinnamon in the treatment of alzheimer's disease
GB201113718D0 (en) Treatment of Dupuytren's Disease